Navigation Links
Researchers Identify Novel Mechanism That Make Cancer Tumors Grow
Date:2/10/2009

Scientists at the Institute for Myeloma and Bone Cancer Research (IMBCR) have uncovered a new pathway that could explain how blood vessels form within tumors.

LOS ANGELES, Feb. 10 /PRNewswire-USNewswire/ -- IMBCR researchers uncovered a new way that cancers orchestrate the production of their own blood supply. Recent studies have shown that many tumors make a protein called pleiotrophin (PTN). They now show that PTN produced by tumor cells in multiple myeloma, a common form of bone marrow-based cancer, changes white cells in the blood called "monocytes" into cells that form the lining of blood vessels called "vascular endothelial cells" (VEC). These VEC cells then become incorporated into the blood vessels that form within tumors.

"This is exciting news, and we feel this will not only have a tremendous impact on hematological tumors, such as myeloma, but other cancers as well," said James R. Berenson, M.D., Medical and Scientific Director of the IMBCR. "By uncovering this unique mechanism, how PTN produced by cancers actually changes circulating white cells into cells that line blood vessels that feed the tumor, we can direct our efforts to create more targeted approaches to eliminate blood supplies for cancers which should dramatically improve therapies for many types of cancers."

Haiming Chen, M.D., Ph.D. is the first author of the research, published this week on the cover of BLOOD. Drs. Berenson and Chen collaborated with scientists at Hemaquest, the Scripps Research Institute, Department of Molecular and Experimental Medicine and Cell Biology at Cedars-Sinai Medical Center, Departments of Neurosurgery, Pathology, and Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at the University of California at Los Angeles.

Part of IMBCR's multi-year research project, "Cure Myeloma Project," this research was funded by grants from the Skirball and Annenberg Foundations, Kramer Family Foundation and the Myeloma Research Fund.

About IMBCR

The Institute for Myeloma and Bone Cancer Research is a non-profit organization headquartered in Los Angeles, California. IMBCR is the only independent cancer research institute working to find improved treatment, and ultimately a cure for multiple myeloma, a cancer of the blood cells that reside in the bone marrow.

IMBCR research has been published in most major oncology journals; Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, Cancer, Clinical Cancer Research, Clinical Lymphoma and Myeloma, Oncogene, and the British Journal of Haematology. www.imbcr.org


'/>"/>
SOURCE Institute for Myeloma and Bone Cancer Research
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s Alumni ... line-up of events for its annual meeting “Coming Home 2017,” an activity-packed weekend ... Home 2017” will be held on Friday January 27 through Sunday, January 29, ...
(Date:1/21/2017)... ... 2017 , ... The Nobel Biocare™ dental implant company is ... its creos™ line of bone regenerative products. Specifically, the Nobel Biocare™ ... creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In addition ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin ... pure essential oils, announced the company had a successful visit to the 2017 ECRM ... event gives companies that work in the nutritional, sports and health industries a chance ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based company ... attended the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding ... range of supplements that keep the body functioning at its peak performance by ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well has launched two ... drinks have been produced in collaboration with Zlatan Ibrahimovic and have been developed ... After a successful launch in Sweden last year, the next generation sports drinks ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 2017  Palladian Health, a leading provider of ... of an opioid management program which assists physicians ... helps stem the growing tide of dependence on ... chronic non-cancer pain (back pain, neck pain, and ... of evidence regarding long-term effectiveness. The ...
(Date:1/20/2017)... January 20, 2017 Avillion LLP, a co-developer ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr ... USA . ... Dr Weinberg has spent more than 17 years as a ... companies to micro-cap biotech. Over the course of his career, he ...
(Date:1/19/2017)... -- Report Details What can be expected ... to grow at the fastest rates? This visiongain report ... opportunities and prospects. Our 190-page report provides 124 ... in the industry and the future market prospects. Our ... all the major categories of the ophthalmic devices market. ...
Breaking Medicine Technology: